
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

May 2019

Commission File Number: 001-38067

**Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)**

**3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 1, 2019, Verona Pharma plc issued a press release announcing the appointment of Nplus1 Singer Advisory LLP as nominated adviser ("NOMAD") and UK corporate broker to the Company with immediate effect. ("The NOMAD Appointment Announcement").

The NOMAD Appointment Announcement is furnished herewith as Exhibit 1 to this Report on Form 6-K.

EXHIBIT INDEX

Exhibit No.	Description
<u>1</u>	The NOMAD Appointment Announcement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERONA PHARMA PLC

Date: May 3, 2019

By: /s/ Claire Poll

Name: Claire Poll

Title: Legal Counsel



Verona Pharma

1 May 2019

Verona Pharma plc

("Verona" or the "Company")

Appointment of Nominated Adviser and UK Broker

Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (â€œVerona Pharmaâ€), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment of Nplus1 Singer Advisory LLP (together with its associates, "N+1 Singer") as nominated adviser and UK corporate broker to the Company with immediate effect.

For further information contact:

Verona Pharma plc

Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications

Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)

Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Mia Gardner (Corporate Broking)

Tel: +44 (0)20 7496 3000

ICR, Inc. (US Media and Investor enquiries)

Darcie Robinson

Tel: +1 203-919-7905

Darcie.Robinson@icrinc.com

Tel. +1 646-277-1282

Stephanie.Carrington@icrinc.com

Stephanie Carrington

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharmaâ€™s product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma is also developing ensifentrine for the treatment of cystic fibrosis and asthma.